Resmed Inc
NYSE:RMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (19.7), the stock would be worth $286.89 (30% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 15.1 | $219.85 |
0%
|
| 3-Year Average | 19.7 | $286.89 |
+30%
|
| 5-Year Average | 24.9 | $362.58 |
+65%
|
| Industry Average | 12.9 | $187.3 |
-15%
|
| Country Average | 14.4 | $208.66 |
-5%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$35.7B
|
/ |
Jan 2026
$2B
|
= |
|
|
$35.7B
|
/ |
Jun 2026
$2.2B
|
= |
|
|
$35.7B
|
/ |
Jun 2027
$2.4B
|
= |
|
|
$35.7B
|
/ |
Jun 2028
$2.6B
|
= |
|
|
$35.7B
|
/ |
Jun 2029
$2.7B
|
= |
|
|
$35.7B
|
/ |
Jun 2030
$2.9B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 15.1 | 21.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 45.5 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 13.8 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 19.8 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 12.9 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 18.9 | 31.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 10.7 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 24.9 | 45.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 30.1 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 9.8 | 24.7 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
31.4B USD | 10.9 | 15.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Resmed Inc
Glance View
ResMed Inc. has built its legacy on a profound, technological commitment to improving the lives of millions worldwide who suffer from sleep-related breathing disorders. Emerging as a beacon in the field of medical device innovation, the company is renowned for its focus on designing and manufacturing equipment to treat sleep apnea, a condition where breathing repeatedly stops and starts during sleep. Their product line, which includes continuous positive airway pressure (CPAP) devices, ventilators, and masks, caters to hospitals, home healthcare settings, and individuals. By addressing this critical health issue, ResMed doesn't just deliver therapeutic equipment; it offers a lifeline to those battling sleep health challenges, ensuring that restful nights translate into healthier days. The company's revenue model pivots around an integrated approach combining hardware sales, software solutions, and cloud-connected offerings. Through its software, ResMed analyzes vast pools of patient data, enabling healthcare providers to tailor and improve therapeutic protocols, thus driving the efficacy of treatment plans. The increasing turn towards digital health technologies has also opened new avenues, with the company's cloud platforms and analytics delivering value-added insights to care providers. This convergence of medical equipment and digital technology provides ResMed not just a steady growth trajectory, but also positions it at the forefront of a healthcare evolution, turning data-driven intelligence into actionable health solutions.
